Antibiotic failure: Beyond antimicrobial resistance
Drug Resistance Updates · 2023-11 · 71 · 101012
DOI: 10.1016/j.drup.2023.101012 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Resistance Updates, 2023-11. Verfasst von Cesar de la Fuente-Nunez und 2 weiteren Autor:innen. Beteiligte Einrichtung: Machine Biology Group, Departments of Psychiatry and Microbiology, Institute for Biomedical Informatics, Institute for Translational Medicine and The…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Sepsis. Die Arbeit wurde bisher 259-mal zitiert (Crossref) und nennt 130 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences, United Therapeutics Corporation.
Abstract (Originalsprache)
Despite significant progress in antibiotic discovery, millions of lives are lost annually to infections. Surprisingly, the failure of antimicrobial treatments to effectively eliminate pathogens frequently cannot be attributed to genetically-encoded antibiotic resistance. This review aims to shed light on the fundamental mechanisms contributing to clinical scenarios where antimicrobial therapies are ineffective (i.e., antibiotic failure), emphasizing critical factors impacting this under-recognized issue. Explored aspects include biofilm formation and sepsis, as well as the underlying microbiome. Therapeutic strategies beyond antibiotics, are examined to address the dimensions and resolution of antibiotic failure, actively contributing to this persistent but escalating crisis. We discuss the clinical relevance of antibiotic failure beyond resistance, limited availability of therapies, potential of new antibiotics to be ineffective, and the urgent need for novel anti-infectives or host-directed therapies directly addressing antibiotic failure. Particularly noteworthy is multidrug adaptive resistance in biofilms that represent 65 % of infections, due to the lack of approved therapies. Sepsis, responsible for 19.7 % of all deaths (as well as severe COVID-19 deaths), is a further manifestation of this issue, since antibiotics are the primary frontline therapy, and yet 23 % of patients succumb to this condition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Machine Biology Group, Departments of Psychiatry and Microbiology, Institute for Biomedical Informatics, Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Ph…
- Centre for Microbial Diseases and Immunity Research, University of British Columbia, Vancouver, Canada. Electronic address: bob@hancocklab.com.
Förderung
- NIGMS NIH HHS
- National Institute of General Medical Sciences
- United Therapeutics Corporation
- Defense Threat Reduction Agency
- Perelman School of Medicine, University of Pennsylvania
- Brain and Behavior Research Foundation
- ACE Foundation
- Procter and Gamble
Zitieren
APA
de la Fuente-Nunez, C., Cesaro, A., & Hancock, R. E. W. (2023). Antibiotic failure: Beyond antimicrobial resistance. Drug Resistance Updates, 71, 101012. https://doi.org/10.1016/j.drup.2023.101012
Vancouver
de la Fuente-Nunez C, Cesaro A, Hancock REW. Antibiotic failure: Beyond antimicrobial resistance. Drug Resistance Updates. 2023;71:101012. doi:10.1016/j.drup.2023.101012
BibTeX
@article{delaFuenteNunez2023,
author = {de la Fuente-Nunez, Cesar and Cesaro, Angela and Hancock, Robert E W},
title = {Antibiotic failure: Beyond antimicrobial resistance},
journal = {Drug Resistance Updates},
year = {2023},
volume = {71},
pages = {101012},
doi = {10.1016/j.drup.2023.101012}
}
EUVIMED